A single week of European funding announcements tells a story that aggregate statistics tend to flatten. At one end, Stockholm's Tandem Health has closed an €86.5 million Series B led by the Scaleup Europe Fund, a vehicle managed by EQT, to build what it calls an AI-native operating system for European clinics. At the other, a Zurich seed-stage company has chosen to spend part of its extension round buying a German competitor rather than simply outspending it. In between sit a €10.5 million fintech infrastructure round in Brussels and a €3 million bioprocessing deal in Zug. The through-line is not the size of the cheques but who is writing them, where the money is going, and what it says about a market that is recovering selectively rather than broadly. Why this matters The European venture ecosystem spent much of the past three years absorbing the consequences of the 2021 excess: down rounds, extended runways, quiet shutdowns. The question investors and founders have been asking is whether the return of large growth rounds signals a genuine reopening of the capital markets or merely a narrowing of the funnel, with capital concentrating around a small number of perceived category winners while the long tail is left to fend for itself. The evidence from the most recent deals points firmly toward the latter. Tandem Health's $100 million raise, as reported by EU-Startups, was supported by existing investors Kinnevik, Northzone, Amino Collective and Visionaries, and follows a previous round announced in June 2025. That is a company being carried forward by a syndicate that already knows it, with a growth-stage fund stepping in to lead. It is a pattern that rewards momentum. Companies that raised in mid-2025 and executed are finding follow-on capital readily available; those that missed that window are finding the door considerably heavier. The involvement of the Scaleup Europe Fund is itself notable. The vehicle exists precisely because European policymakers concluded that the continent's scale-up financing gap, the stage at which promising companies historically decamped to American investors or American listings, was a structural weakness rather than a cyclical one. Seeing it lead a nine-figure round for a Nordic health technology company is an early test of whether that thesis translates into deal flow. The healthcare concentration Two of the four venture deals under review are in healthcare, and this is not coincidence. Tandem Health is building an AI medical assistant for clinics; Aeon, the Zurich company, is developing AI-powered whole-body health check-ups and has, according to an EU-Startups exclusive, closed a seed extension that takes its total seed funding above €12 million ($14 million), building on an €8.2 million raise in June 2025. Alongside that extension, Aeon acquired Aware Health, a German blood diagnostics platform. The attraction of European healthcare for AI-focused investors is straightforward. The continent's health systems are fragmented across national borders but share common pressures: ageing populations, clinician shortages and administrative burdens that consume a substantial share of medical time. An AI layer that removes documentation work or enables preventive screening at scale addresses a cost problem that public payers are increasingly willing to fund. Crucially, Europe's regulatory environment, often cited as a drag, becomes an asset here. A company that has navigated medical device rules and data protection requirements across several European jurisdictions holds a moat that a Silicon Valley entrant cannot easily replicate. The Aeon transaction deserves particular attention because it inverts the usual seed-stage playbook. Acquisitions at this stage are rare; founders typically prefer to build rather than buy, and investors typically prefer their capital to fund product and hiring rather than integration risk. That Aeon chose to acquire suggests two things. First, that consolidation is arriving earlier in the cycle than it did in previous ones, as capital-constrained companies in adjacent niches become available at reasonable prices. Second, that the AI-driven health check-up space is one where breadth of diagnostic data matters, and buying a blood diagnostics platform is a faster route to that breadth than building one. Expect more of this. A seed-stage environment in which some companies can raise extensions and others cannot is, by definition, an environment that produces acquirers and targets. Infrastructure over applications The Chift and Ferm Labs rounds illustrate a second trend: investor preference for picks-and-shovels businesses over consumer-facing bets. Chift, based in Brussels, provides what it describes as a financial connectivity layer, allowing software vendors to plug their products into the accounting, banking and invoicing tools their customers already use. Its €10.5 million Series A was led by BlackFin Capital Partners, a specialist European fintech investor managing more than €4 billion, per EU-Startu